{"filings":[{"id":2961400,"accession_number":"0001213900-26-101405","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-09-18T20:05:16+00:00","items":["5.07"],"status":"ready","headline":"20/20 Biolabs shareholders approve 10x increase in authorized common stock to 500M shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved charter amendment raising authorized common stock from 50 million to 500 million shares (10x increase).","Vote totals: 3,028,609 for, 1,155,607 against, 72,621 abstentions at Sept 16 adjourned meeting.","Annual meeting was adjourned Aug 18 after proposal lacked sufficient votes; quorum was met Sept 16.","4,256,837 shares represented (about 35% of 12,251,198 outstanding) constituted a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2796519,"accession_number":"0001213900-26-098792","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-09-10T20:10:32+00:00","items":["3.01"],"status":"ready","headline":"20/20 Biolabs gets Nasdaq equity non-compliance notice; delisting risk","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Sept 3, 2026, Nasdaq notified 20/20 Biolabs of non-compliance with $2.5M stockholders' equity rule; reported equity $1.62M.","Company has 45 days to submit compliance plan; if accepted, extension up to 180 days possible.","Also previously notified July 17, 2026 of bid price non-compliance; must regain $1.00 bid by Jan 13, 2027.","Failure to cure equity by Jan 13, 2027 would also disqualify additional bid-price cure period.","Company intends to monitor and consider options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2632398,"accession_number":"0001213900-26-096743","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-09-02T20:32:39+00:00","items":["7.01","9.01"],"status":"ready","headline":"20/20 Biolabs furnishes Sept 2026 investor presentation; no financial detail disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["20/20 Biolabs (AIDX) furnished an investor presentation, dated September 2026, for use in a Sept 2, 2026 investor webinar.","Presentation text included in the exhibit contains only a cover slide; no revenue, EPS, pipeline, or guidance figures were provided.","CEO Jonathan Cohen signed the 8-K; no operational or financial updates were disclosed in the filing body or exhibit.","Material news content could not be extracted from the available exhibit text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2338716,"accession_number":"0001213900-26-091438","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-08-19T13:19:15+00:00","items":["5.07"],"status":"ready","headline":"20/20 Biolabs annual meeting: directors elected, auditor ratified, charter amendment fails, adjourned to Sept 16","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six directors elected: Jonathan Cohen, John G. Compton, Richard M. Cohen, Prasanth Reddy, John W. Rollins, Michael A. Ross; each received >2.6M votes for.","Ratified dbbmckennon as independent auditor for FY2026: 4,105,584 for, 132,421 against, 18,832 abstentions.","Approved 2026 Equity Incentive Plan: 2,183,335 for, 573,931 against, 1,433,721 broker non-votes.","Proposal 3 (Charter Amendment) failed to get sufficient votes; meeting adjourned to Sept 16, 2026 at 10:00 a.m. ET to solicit more proxies.","Quorum: 4,256,837 shares represented out of 12,251,198 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2300444,"accession_number":"0001213900-26-090746","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-08-17T20:05:37+00:00","items":["2.02","9.01"],"status":"ready","headline":"20/20 BioLabs Q2 revenue up 37% to $0.7M; OneTest revenue up 47%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 total revenue $0.7M, up 36.5% YoY; OneTest revenue $0.7M, up 47.1%, 95.3% of total.","Gross profit $0.3M, up 86.6%; gross margin 41.7% vs 30.5%.","Net loss $1.5M vs $0.8M; cash $4.5M, up from $1.0M; convertible note debt eliminated.","Vermont and Maryland firefighter programs expected to generate >$1.0M revenue through 2026; >35,000 firefighters tested by year-end.","Raised $6.0M Series E preferred in H1 2026; up to $40M available; standstill with Streeterville."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":1083946.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2068996,"accession_number":"0001213900-26-085514","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-08-05T16:00:42+00:00","items":["7.01","9.01"],"status":"ready","headline":"20/20 Biolabs holds investor webinar on August 5, 2026; no specific financial or operational details released","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished investor presentation for August 5, 2026 webinar under Regulation FD.","Presentation materials are not incorporated by reference and are not deemed filed with the SEC.","No financial results, guidance, or material events were disclosed in the filing text or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1803996,"accession_number":"0001213900-26-080432","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-07-22T20:45:12+00:00","items":["1.01","3.01","9.01"],"status":"ready","headline":"20/20 Biolabs enters standstill with Streeterville; receives Nasdaq bid price deficiency notice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Standstill agreement with Streeterville: 120-day forbearance on conversion of Series E preferred unless stock price >10% above Nasdaq Minimum Price.","Nasdaq notified company of non-compliance with $1.00 bid price rule for 30 consecutive business days through July 16, 2026.","Company has 180 calendar days (until January 13, 2027) to regain compliance by closing bid price at $1.00 for 10 consecutive business days.","If not compliant by Jan 13, 2027, may qualify for a second 180-day period if it meets other listing standards.","Company intends to monitor bid price and consider available options to cure the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1386236,"accession_number":"0001213900-26-074182","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-07-01T19:28:22+00:00","items":["7.01","9.01"],"status":"ready","headline":"20/20 Biolabs furnishes investor presentation for July 1 webinar; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1 for Regulation FD purposes.","No specific financial or operational data provided in the filing.","Company intends to use materials in investor webinar on July 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":668436,"accession_number":"0001213900-26-061039","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-05-26T20:28:45+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"20/20 Biolabs reduces stockholder meeting quorum from majority to one-third","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted Amendment No. 1 to Bylaws on May 19, 2026.","Quorum required for stockholder meetings reduced from majority to one-third of outstanding shares.","Amendment to Section 2.5 of Amended and Restated Bylaws; effective immediately.","No other changes to stockholder rights or company governance structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554518,"accession_number":"0001213900-26-059526","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-05-20T20:10:53+00:00","items":["2.02","9.01"],"status":"ready","headline":"20/20 BioLabs Q1 revenue $0.4M, net loss $2.2M; expects Q2 rebound from firefighter programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $0.4M vs $0.6M YoY; net loss $2.2M vs $0.8M; gross margin 17.8% vs 29.9%.","Cash $4.2M (vs $1.0M Dec 2025) after $5M private placement; deferred revenue $0.5M.","State-funded firefighter cancer screening programs expected to drive meaningful Q2 revenue; second state committed.","Launched OneTest for Longevity with IBM; exclusive U.S. CKD license from ROKIT Healthcare.","Medicare MCED Screening Act signed Feb 2026; pathway for Medicare coverage by 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":353375.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91526,"accession_number":"0001213900-26-048257","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"20/20 Biolabs cuts warrant exercise price to $2.25, from $11.42/$8.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On April 23, 2026, amended Streeterville warrants lowering exercise price to $2.25/share.","Warrants cover 3,627,627 shares; prior prices were $11.42 and $8.00.","Company retains right to terminate amendment within 90 days on 2 days' notice.","Warrants issued in conjunction with $5M+ in convertible notes and Series E preferred.","Reduction implies significant potential dilution for existing common shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91525,"accession_number":"0001213900-26-037770","cik":1139685,"company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"20/20 BioLabs FY 2025 revenue $2.0M (+17%); gross margin expands; $5M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.0M (+17% YoY); gross profit $0.6M (+68%); gross margin 29.6% vs 20.6%.","Operating expenses down 35% to $3.9M; net loss improved 33% to ($3.7)M; cash $1.0M.","Completed $5.0M private placement Feb 2026; up to $40M available in tranches.","MDH awarded $520K to 18 fire departments for OneTest MCED; Medicare MCED pathway law signed Feb 2026.","Launched OneTest for Longevity with IBM AI; exclusive license with ROKIT Healthcare for CKD prediction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10152048.837600002,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}